Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid-Reference-Cited by-同舟云学术

Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid

Published:2018-09-18 Issue: Volume: Page:
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:

Author:

Chirehwa Maxwell T¹^ORCID,McIlleron Helen¹,Wiesner Lubbe¹,Affolabi Dissou²,Bah-Sow Oumou³,Merle Corinne⁴⁵,Denti Paolo¹,N’Diaye Alimatou,Mbaye Ibrahima Mariétou,De Jong Bouke,Anagonou Severin,Diatema Salim,Gomina Ibrahima Khalil,Gossa Severin,Tanimomo Blanche,Bekou Wilfried,Galperine Tatiana,Furco Andre,Diallo Mouctar,Bah Boubacar,Bah Falilou,Barry Néné,Barry Abdourahmane,Barry Sadjo,Barry Mamadou Telly,Sylla Aissatou Bah,Barry Alpha Mamadou,Sarr Marie,Ngom Ndéye Fatou,Ndiaye Kine,Sakho Diama,Ngom Justine,Ba Fatoumata,Seck Amadou,Furco Andre,Floyd Sian,Branson Keith,Glynn Judith,Phillips Dany,Oubaya Nadia,Saint-Martin Caroline,

Affiliation:

1. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa

2. National Programme for Tuberculosis and Pulmonary Diseases, Cotonou, Benin

3. Service de Pneumo-Phtisiologie, Hopital Ignace Deen, Conakry, Guinea

4. London School of Hygiene & Tropical Medicine, London, UK

5. UNICEF/UNDP/World Bank/WHO Special Programme on Research and Training in Tropical Diseases (TDR), Geneva, Switzerland

Funder

European & Developing Countries Clinical Trials Partnership

Wellcome Trust

National Research Foundation of South Africa

National Institute of Allergy and Infectious Diseases

National Institutes of Health